Thrombocytopenia

Table of Contents

  1. Table of Contents
  2. Overview
  3. Epidemiology
  4. Pathophysiology
  5. Etiology and Risk Factors
  6. Clinical Presentation
  7. Diagnosis
  8. Treatment
  9. Complications
  10. Prognosis
  11. Prevention
  12. Recent Research and Advances
  13. Research Papers
  14. Connections
  15. Featured Videos

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. References
  13. Featured Videos

Back to Table of Contents

1. Overview

Thrombocytopenia is defined as a platelet count below the lower limit of normal, conventionally set at 150 × 10⁹/L (150,000/µL). Platelets are anucleate cell fragments derived from bone marrow megakaryocytes that play a fundamental role in primary hemostasis — adhering to sites of vascular injury, activating, and aggregating to form the initial platelet plug that is subsequently reinforced by the fibrin clot of secondary hemostasis.

Thrombocytopenia can result from decreased platelet production, increased platelet destruction or consumption, platelet sequestration, or dilution. The clinical significance ranges from incidental, asymptomatic mild thrombocytopenia (platelet count 100–149 × 10⁹/L) to life-threatening hemorrhage in severe thrombocytopenia (<20 × 10⁹/L). The most clinically important etiologies include immune thrombocytopenia (ITP), heparin-induced thrombocytopenia (HIT), and thrombotic thrombocytopenic purpura (TTP), each with distinct pathophysiology and management.

Back to Table of Contents

2. Epidemiology

Thrombocytopenia is common across clinical settings. In hospitalized patients, it is estimated to occur in 25–41% of patients, most often related to sepsis, medications, or critical illness. Immune thrombocytopenia (ITP) has an incidence of approximately 2–10 cases per 100,000 adults per year; the pediatric form is more common (4–8 per 100,000 children per year) and usually follows a viral illness with spontaneous resolution in 80–90% of cases. In adults, ITP is more common in women of childbearing age (female-to-male ratio ~3:1), though this sex predilection diminishes with age.

Gestational thrombocytopenia (mild, incidental thrombocytopenia of pregnancy) occurs in approximately 5–8% of all pregnancies and accounts for 70–80% of thrombocytopenia in pregnancy. Heparin-induced thrombocytopenia (HIT) occurs in 0.1–5% of patients receiving unfractionated heparin, depending on patient population and duration of exposure. Drug-induced thrombocytopenia from other agents (e.g., quinine, vancomycin, valproic acid) has an overall incidence of ~10 cases per million persons per year.

Back to Table of Contents

3. Pathophysiology

Platelet Production and Destruction

Platelet production occurs in bone marrow through megakaryopoiesis: hematopoietic stem cells differentiate under the influence of thrombopoietin (TPO) (produced primarily by the liver) into megakaryocyte progenitors, mature megakaryocytes, and ultimately into platelets through a process of cytoplasmic fragmentation (thrombopoiesis). Each megakaryocyte generates 1,000–3,000 platelets. Platelets circulate for approximately 7–10 days before being cleared by the reticuloendothelial system (spleen and liver).

Thrombocytopenia arises through three principal mechanisms:

  1. Decreased production: Bone marrow failure (aplastic anemia), infiltration (leukemia, lymphoma, metastatic cancer, myelofibrosis), ineffective thrombopoiesis (B12/folate deficiency, myelodysplastic syndrome), chemotherapy/radiation-induced suppression, viral infections (HIV, hepatitis C, EBV).
  2. Increased destruction or consumption:
    • Immune-mediated: ITP — autoantibodies (predominantly IgG) bind platelet surface glycoproteins (GPIIb/IIIa, GPIb/IX), leading to accelerated Fc-receptor-mediated phagocytosis by splenic macrophages. CD8+ T cells also contribute to megakaryocyte and platelet destruction. In HIT, IgG antibodies against complexes of heparin and platelet factor 4 (PF4) bind platelet FcγRIIA receptors, causing platelet activation, consumption, and paradoxically thrombosis.
    • Non-immune: Mechanical destruction in microangiopathic hemolytic anemias (TTP, HUS, DIC); consumptive coagulopathy.
  3. Sequestration: Splenomegaly (from cirrhosis, portal hypertension, myeloproliferative neoplasms) sequesters up to 90% of the total platelet pool (normally ~33%), reducing circulating platelet count.

Coagulation Impact

Platelets contribute to secondary hemostasis by providing a phospholipid surface for assembly of the prothrombinase complex (FXa–FVa) and the tenase complex (FIXa–FVIIIa), amplifying thrombin generation approximately 300,000-fold compared to reactions in solution. Severe thrombocytopenia thus impairs both primary hemostasis and the amplification of secondary hemostasis, explaining the propensity for mucocutaneous and internal bleeding.

Back to Table of Contents

4. Etiology and Risk Factors

Back to Table of Contents

5. Clinical Presentation

Bleeding Patterns by Severity

Clinical Features

Back to Table of Contents

6. Diagnosis

Initial Workup

Back to Table of Contents

7. Treatment

Immune Thrombocytopenia (ITP)

HIT Management

Platelet Transfusion Thresholds

Back to Table of Contents

8. Complications

Back to Table of Contents

9. Prognosis

Prognosis depends critically on the underlying etiology. Pediatric ITP is self-limiting in ~80–90% of cases within 6–12 months. Adult ITP is more often chronic; approximately 20–30% achieve durable remission with first-line therapy, while many require long-term second-line treatment. With TPO-RAs, most patients maintain sustained platelet responses, though long-term treatment may be necessary. HIT, if recognized and managed promptly with alternative anticoagulation, carries a good prognosis; unrecognized or inadequately treated HIT is associated with a 30-day thrombosis rate of ~50%. Thrombocytopenia secondary to bone marrow failure (aplastic anemia, leukemia, MDS) carries the prognosis of the underlying disease. TTP has a mortality rate of >90% untreated but falls to 10–20% with plasma exchange.

Back to Table of Contents

10. Prevention

Back to Table of Contents

11. Recent Research and Advances

The field of ITP has been transformed by thrombopoietin receptor agonists, with romiplostim and eltrombopag now standard second-line options. Newer TPO-RAs — avatrombopag and lusutrombopag — have expanded the oral treatment armamentarium. Fostamatinib, an SYK inhibitor, represents a mechanistically distinct approach targeting macrophage Fc receptor signaling. The anti-neonatal Fc receptor (FcRn) inhibitor efgartigimod alfa (Vyvgart) has shown efficacy in Phase 3 ITP trials (ADAPT+), rapidly reducing pathogenic IgG antibodies including anti-platelet autoantibodies, offering a novel mechanism distinct from all existing therapies.

For HIT, real-world data increasingly support direct oral anticoagulants (particularly rivaroxaban and apixaban) for treatment and secondary prevention, avoiding the complexity of parenteral non-heparin anticoagulants. Better understanding of anti-PF4 antibody biology — including the recognition of spontaneous, non-heparin-triggered HIT-like syndromes — has refined serologic testing and management of immune-mediated thrombocytopenia more broadly. Caplacizumab (anti-VWF nanobody) in combination with plasma exchange and immunosuppression has become standard of care for TTP, reducing TTP-related mortality and relapse.

Back to Table of Contents

Research Papers

The following PubMed topic searches return current peer-reviewed literature relevant to this condition. Each link opens a live PubMed query.

Back to Table of Contents

Connections

Back to Table of Contents

Video Thumbnail

Doctor explains LOW PLATELET COUNT (Thrombocytopenia) | Causes, symptoms and more

Video Thumbnail

Thrombocytopenia | Signs and Symptoms and Approach to Causes

Video Thumbnail

Low Platelets: Causes, conditions and treatment